MTOR and lymphoma: Table 1 shows an exhaustive list of the dual class I PI3K and mTOR inhibitors. Table 2 summarizes the clinical data available for patients that are affected by lymphoma enrolled in phase I/II studies with such a class of compounds. The chemical structures, International Union of Pure and Applied Chemistry (IUPAC) names, and molecular weights for all of the compounds are shown in Table 3 or Table S1, depending on their current clinical development stage.